These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 25118479)

  • 1. An in vivo model for the study of ovarian cancer and the persistence of characteristic mutations in xenografts.
    Li Y; Gu YJ; Liu CN; Yue TF
    Eur J Gynaecol Oncol; 2014; 35(4):387-92. PubMed ID: 25118479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
    BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternate molecular genetic pathways in ovarian carcinomas of common histological types.
    Willner J; Wurz K; Allison KH; Galic V; Garcia RL; Goff BA; Swisher EM
    Hum Pathol; 2007 Apr; 38(4):607-13. PubMed ID: 17258789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular pathology of ovarian cancer.
    Sanseverino F; D'Andrilli G; Petraglia F; Giordano A
    Anal Quant Cytol Histol; 2005 Jun; 27(3):121-4. PubMed ID: 16121632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of novel mutations of ovarian cancer-related genes from RNA-sequencing data for Japanese epithelial ovarian cancer patients.
    Nagasawa S; Ikeda K; Horie-Inoue K; Sato S; Takeda S; Hasegawa K; Inoue S
    Endocr J; 2020 Feb; 67(2):219-229. PubMed ID: 31748433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characterization of 103 ovarian serous and mucinous tumors.
    Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
    Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.
    Wu R; Hendrix-Lucas N; Kuick R; Zhai Y; Schwartz DR; Akyol A; Hanash S; Misek DE; Katabuchi H; Williams BO; Fearon ER; Cho KR
    Cancer Cell; 2007 Apr; 11(4):321-33. PubMed ID: 17418409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTEN loss and HOXA10 expression are associated with ovarian endometrioid adenocarcinoma differentiation and progression.
    Tanwar PS; Kaneko-Tarui T; Lee HJ; Zhang L; Teixeira JM
    Carcinogenesis; 2013 Apr; 34(4):893-901. PubMed ID: 23276799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
    Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
    Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis.
    Kurman RJ; Visvanathan K; Roden R; Wu TC; Shih IeM
    Am J Obstet Gynecol; 2008 Apr; 198(4):351-6. PubMed ID: 18395030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
    Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
    Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocyte growth factor secreted by ovarian cancer cells stimulates peritoneal implantation via the mesothelial-mesenchymal transition of the peritoneum.
    Nakamura M; Ono YJ; Kanemura M; Tanaka T; Hayashi M; Terai Y; Ohmichi M
    Gynecol Oncol; 2015 Nov; 139(2):345-54. PubMed ID: 26335595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular pathology of epithelial ovarian cancer.
    Christie M; Oehler MK
    J Br Menopause Soc; 2006 Jun; 12(2):57-63. PubMed ID: 16776856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
    Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
    Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling genetic and clinical heterogeneity in epithelial ovarian cancers.
    Lawrenson K; Sproul D; Grun B; Notaridou M; Benjamin E; Jacobs IJ; Dafou D; Sims AH; Gayther SA
    Carcinogenesis; 2011 Oct; 32(10):1540-9. PubMed ID: 21859834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic alteration and immunohistochemical staining patterns of ovarian high-grade serous adenocarcinoma with special emphasis on p53 immnnostaining pattern.
    Lee SH; Kim H; Kim WY; Han HS; Lim SD; Kim WS; Kim S; Hwang TS
    Pathol Int; 2013 May; 63(5):252-9. PubMed ID: 23714252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo.
    Mullany LK; Fan HY; Liu Z; White LD; Marshall A; Gunaratne P; Anderson ML; Creighton CJ; Xin L; Deavers M; Wong KK; Richards JS
    Oncogene; 2011 Aug; 30(32):3522-36. PubMed ID: 21423204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.
    Nodin B; Zendehrokh N; Sundström M; Jirström K
    Diagn Pathol; 2013 Jun; 8():106. PubMed ID: 23800114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.